Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | PLG | P00747 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.36 |
| ▸ | PLAT | P00750 | 2/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17420649 | 0.87 | RXRA (0.41) | IRAK4KCNK3KCNK9MKNK1MKNK2 | |
| SCHEMBL30628201 | 0.87 | RXRA (0.41) | IRAK4KCNK3KCNK9MKNK1MKNK2 | |
| SCHEMBL30087594 | 0.83 | IRAK4 (0.54) | IRAK4KCNK3KCNK9KCNN4RXRA | |
| SCHEMBL30087624 | 0.81 | EPHX2 (0.43) | KCNN4 | |
| SCHEMBL17420436 | 0.81 | MAPT (0.41) | KCNK3KCNK9MKNK1MKNK2RXRA | |
| SCHEMBL24176727 | 0.79 | DRD2 (0.45) | KCNK3KCNK9RXRARXRBRXRG | |
| SCHEMBL30087619 | 0.78 | PARP10 (0.46) | IRAK4POLBF2PLGPLAU | |
| SCHEMBL30087623 | 0.77 | MEN1 (0.42) | KCNN4RXRAPOLBALDH1A1 | |
| SCHEMBL7809562 | 0.76 | KCNH2 (0.39) | IRAK4MKNK1MKNK2RXRARXRB | |
| SCHEMBL30087600 | 0.75 | PARP10 (0.46) | IRAK4POLBF2PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320192-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DEUTERX LLC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20230242504-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DEUTERX LLC (US) | 2023-08-03 | — | — | US | disclosed |
| US-11535603-B1 | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same | DEUTERX, LLC (US) | 2022-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242504-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | EGLN3, HPGDS, EGLN2 | IRAK4 1975/4885KCNK3 1417/4885KCNK9 2674/4885 |
| US-20250320192-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | EGLN3, HPGDS, EGLN2 | IRAK4 1975/4885KCNK3 1417/4885KCNK9 2674/4885 |
| US-11535603-B1 | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same | EGLN3, HPGDS, EGLN2 | IRAK4 1975/4885KCNK3 1417/4885KCNK9 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.